11/02/2019 23:14:16

Veritas Pharma Announces the Resignation of CEO, Dr. Lui Franciosi

VANCOUVER, British Columbia, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces the resignation of its President, CEO and Director, Dr. Lui Franciosi.  Company Interim CFO, Mr. Peter McFadden will fill the executive roles in the interim until a qualified replacement is found.

Dr. Franciosi stated, “It has been a challenging year with the regulatory delays in starting the Puerto Rico human study of CTL-X and the need to raise funds for medical cannabis research.  I am pleased to see the study approval has finally come through and that potential funding for Cannevert’s important scientific work has been secured, which means that the Veritas and Cannevert are now set for growth under new leadership. My work with Veritas has been a great experience, however I am extremely excited to give my primary focus to the science side of the business, and I will be available to the company at an advisory capacity to ensure seamless transition.”

Mr. McFadden stated, “The Veritas Board would like to thank Lui for his commitment to investors and to advancing the science behind medical cannabis.”  Dr. Franciosi will continue to assist both companies in an operational capacity.

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar markets according to Deloitte’s Insights and Opportunities.

Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website: www.veritaspharmainc.com

On behalf of the Board of Directors

"

Mr.

Peter McFadden"

Mr. Peter McFadden

Interim President and Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Contact

Investor and Public Relations

at:

Telephone: +1.604.827.5520

Email: ir@veritaspharmainc.com

Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

Logo.PNG

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Apr
I:SP500
  Hejsa.   Lige lidt læsestof til påsken.   Langsigtet konjunktur:   Overraskende stigning i de le..
48
18 Apr
 
Jeg har modtaget flg. fra Delfin : "Nå, så er jeg blokeret på EI. Hvorfor ved jeg ikke. Jeg har ikke..
39
17 Apr
VELO
  Den eneste TA-ekspert var for mig alpehue, og nogle ganske få andre. Langt de fleste, som udtaler ..
28
20 Apr
NOVO-B
En lille påskehilsen fra Alpe, med mulighed for Novo.   https://invst.ly/al3nf  
23
17 Apr
 
EI hvorfor har I slettet mit indlæg 414414 og hele debatten om hvad en moderater bør blande sig i ? ..
21
21 Apr
NOVO-B
Det var bare mig, der havde spurgt Alpe om en streg på Novo, hvorefter jeg modtog dette, og gerne må..
20
21 Apr
NOVO-B
Er du dum, VI VIL HAVE ALPE TILBAGE
12
17 Apr
TEVA
Den er også svær lige nu fordi mange korte og lange signaler krydser ind over hinanden lige nu. Men ..
11
20 Apr
ZEAL
Nedenfor er en artikle fra Ritzau fra 2018 som gennemgår situationen med Zealand Pharmas tyske samar..
10
19 Apr
 
EI har spillet fallit, jeg har været med her i 15 år, og folk der kun er her for at ødelægge debatte..
10

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Start of Day Message
2
Nevada Joint Venture Deal Clears All Regulatory Conditions
3
Franklin Electric Declares Payment of Quarterly Cash Dividend
4
Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2
5
BoxScore Brands Board of Directors Announces the Addition of Consumer Products Veteran Michael P. Flanagan as CEO and Member of the Board of Directors as Well as a New Strategic Direction

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 April 2019 17:47:26
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB6 - 2019-04-22 18:47:26 - 2019-04-22 17:47:26 - 1000 - Website: OKAY